Latest stories on ABCL
AbCellera to Present at Upcoming Investor Conferences in November 2026
StockTitan52 · neutralproduct/pr
ABCL Spotlight: Phase 2 Data Show ABCL635 Cut Vasomotor Symptoms by 8.8 Per Day at Week Four
MarketChameleon74 · bullishproduct/pr
AbCellera Has Promising Menopause Data, But Much Of The Opportunity Is Priced In
Seeking Alpha48 · neutralanalyst
UBS initiates AbCellera stock with buy rating on menopause drug potential
Investing.com Analyst Ratings64 · neutralanalyst
AbCellera initiated with a Buy at UBS
The Fly63 · neutralanalyst
AbCellera Tees Up New Phase 1/2 ABCL635 Data at TMS, Spotlighting a Long-Acting Non-Hormonal Approach to Hot Flashes
October 9, 2026
MarketChameleon58 · neutralproduct/pr
AbCellera to present Phase 1/2 data for ABCL635 at TMS 2026 Annual Meeting
The Fly56 · neutralproduct/pr
AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting
StockTitan56 · neutralproduct/pr
AbCellera sets November 9 date for Q3 2026 results and a 3:00 p.m. Pacific earnings call
MarketChameleon50 · neutralearnings
AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026
StockTitan50 · neutralgeneral
AbCellera Biologics call volume above normal and directionally bullish
The Fly62 · neutralgeneral
JPMorgan initiates AbCellera stock coverage with overweight rating
Investing.com Analyst Ratings61 · neutralanalyst
AbCellera initiated with an Overweight at JPMorgan
The Fly63 · neutralanalyst
Goldman Sachs resumes AbCellera stock coverage with neutral rating
Investing.com Analyst Ratings50 · neutralanalyst
AbCellera resumed with a Neutral at Goldman Sachs
The Fly50 · neutralanalyst
ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know - qz.com
Quartz68 · bullishgeneral
AbCellera and Recursion Pharmaceuticals: two AI-drug stocks, two different stories
Investing.com Markets54 · neutralgeneral
AbCellera Biologics call volume above normal and directionally bullish
The Fly62 · neutralgeneral
AbCellera Sets October 2026 Spotlight for ABCL635 Phase 2 Menopause Symptom Data
September 17, 2026
MarketChameleon63 · neutralproduct/pr
AbCellera to present Phase 2 Data for ABCL635 at IMS Congress on Menopause
The Fly59 · neutralproduct/pr
AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026
StockTitan59 · neutralproduct/pr
AbCellera Biologics call volume above normal and directionally bullish
The Fly62 · neutralgeneral
AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026
StockTitan56 · neutralgeneral
HHS said to be eyeing two new FDA deputy commissioners for technology and drugs
Seeking Alpha63 · neutralgeneral